Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock

Posted: January 13, 2025 at 2:54 am

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the closing of its previously announced public offering of 5,000,000 shares of common stock at $0.85 per share for gross proceeds of approximately $4.25 million.

More:
Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock

Related Posts